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Abstract: Lymphoid malignancies frequently harbor genetic mutations leading to aberrant activation
of nuclear factor-κB (NF-κB) signaling; in normal cells, this pathway has important roles in the
control of cell growth, survival, stress responses, and inflammation. Malignancies with mutations in
NF-κB pathway components can derive from all cell stages of mature B-cell development; however,
aberrant NF-κB activity is particularly prevalent in aggressive subtypes of non-Hodgkin lymphoma
and myeloma. NF-κB activation is mediated by two separate pathways, the canonical and alternative
pathway, and five downstream transcription factor subunits. Recent findings implicate a predominant
role for distinct NF-κB pathways and subunits in certain lymphoma subtypes and myeloma; findings
which are complemented by the realization that individual NF-κB subunits can have unique,
non-redundant biological roles in the putative tumor precursor cells, including activated B cells,
germinal center B cells and plasma cells. The knowledge gained from these studies may be exploited
for the development of therapeutic strategies to inhibit aberrant NF-κB activity at the level of the
transcription-factor subunits and their target genes, as global inhibition of the pathway is toxic.
Here, we provide an overview on the role of aberrant NF-κB activation in aggressive lymphoid
malignancies and discuss the potential importance of individual NF-κB subunits in the pathogenesis
of tumor subtypes.
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1. Introduction
Cancers of the B-cell lineage arise from malignant transformation of B cells and plasma cells (PCs)
at various stages of differentiation. The majority of B-cell lymphomas and PC malignancies originate
from B cells that have undergone the germinal center (GC) B-cell reaction of the T cell-dependent
immune response that is essential for our immunity against foreign antigens [1,2]. During the
GC reaction, B cells recognizing the invading pathogen undergo somatic hypermutation in their
rearranged immunoglobulin variable (IgV) genes in order to generate high-affinity PCs and memory B
cells [3,4]. Another process occurring during the GC reaction is Ig class switch recombination, in which
the B cell switches from the expression of IgM to other Ig classes with different effector functions.
Errors during the DNA-modifying processes of somatic hypermutation and class switch recombination,
in addition to mistakes occurring during the rearrangement of the antibody genes in developing B
cells, can cause genetic aberrations (e.g., chromosomal translocations and deletions) that activate
oncogenes or inactivate tumor suppressor genes [5]. A common pathogenic mechanism in the genesis
of lymphomas and PC malignancies is the deregulation of proto-oncogenes (e.g., MYC, BCL2, BCL6)
and the inactivation of tumor suppressor genes (e.g., PRDM1) that have crucial functions in the control
of normal B-cell and PC development through genetic aberrations [6]. Recently, deregulated activity of
the NF-κB signaling pathway due to genetic mutations emerged as a major driver in the pathogenesis
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of several B-lineage malignancies, especially in aggressive subtypes of B-cell non-Hodgkin lymphoma
(B-NHL) and in multiple myeloma (MM), an incurable tumor of PCs.
2. NF-κB
The NF-κB signaling pathway plays a crucial role in multiple biological processes, including
survival, growth, inflammation and stress responses, across many cell types, through regulation of
gene expression [7,8]. NF-κB signaling ultimately leads to the activation of five NF-κB transcription
factor subunits, c-REL, RELA (p65), RELB, p50 (and its precursor p105), and p52 (and its precursor
p100) which associate as hetero or homodimers (Figure 1). The c-REL, RELA and RELB subunits are
the drivers of transcription through ‘transactivation domains’ at the C-termini. Receptor-mediated
activation of the dimers causes their translocation to the nucleus, where they regulate the expression of
NF-κB target genes. The NF-κB transcription factors cluster into two groups; the RELA, c-REL and p50
subunits mediate the canonical NF-κB pathway, which in B cells is activated by stimulation through
the B-cell receptor (BCR), Toll-like receptors and CD40 ligation [9,10]. The major heterodimers are
RELA/p50 and c-REL/p50; these are retained in the cytoplasm by inhibitory κBα (IκBα) and released
following IκB kinase (IKK)-mediated phosphorylation and subsequent proteasomal degradation of
IκBα, causing the translocation of the heterodimers to the nucleus. Nuclear translocation of NF-κB
transcription factors thus indicates NF-κB pathway activation. The RELB/p52 heterodimer of the
alternative (or non-canonical) pathway is activated in B cells by CD40 ligation, B-cell activating
factor (BAFF) or lymphotoxin-β (LTβ) receptor [9–11]. Activation of the alternative pathway results
in the release and stabilization of NF-κB-inducing kinase (NIK) from the TRAF2/TRAF3/cIAP1/2
complex [12]. NIK activates IKKα, which in turn induces cleavage of p100 (which is bound to RELB)
by phosphorylation; this allows for nuclear translocation of the RELB/p52 heterodimer. In certain
cell systems, crosstalk between the pathways may occur. Thus, NIK has been found to also activate
the canonical pathway [13–16], and in some contexts, canonical NF-κB subunits can transcriptionally
upregulate expression of the alternative subunits [17]. Additionally, CD40 is known to activate both
the canonical and alternative NF-κB pathways (Figure 1) [9,10]. A potential crosstalk between the
two pathways may need to be taken into consideration when interpreting the downstream effects of a
particular NF-κB-inducing stimulus.
3. Germinal Center Reaction and NF-κB
While the roles of NF-κB in early B-cell development and in the survival of naïve B cells
(the precursors of GC B cells) have been firmly established [9,10,18], the function of NF-κB in the
later stages of mature B-cell development—encompassing the GC reaction and differentiation of GC
B cells into memory B cells or PCs—could not be investigated for technical reasons, in particular
since constitutional knockout mice of NF-κB subunits either lack or have severely impaired GC
formation [9,10,18]. Recent studies could provide new insights into NF-κB activation and the roles of
the separate NF-κB transcription factor subunits during late B-cell differentiation, which comprises the
cellular counterparts of the various types of lymphomas and PC malignancies.
The GC, which is the place where the adaptive immunity in the antibody system is generated [19],
is a transient structure developing within peripheral lymphoid organs in response to invading
pathogens [3]. Guided by T cell help, antigen-activated B cells migrate from the interfollicular region
to the primary follicle. The B cells rapidly divide within the follicle until day 7 of the GC response,
when a mature, polarized GC microenvironment is formed, which comprises two functionally distinct
compartments—a dark zone and a light zone [4,20–22]. Dark zone GC B cells proliferate vigorously
and somatically hypermutate their IgV genes, thus generating a large number of antibody mutants in
a short time frame. These cells move to the light zone where B cells are selected for improved antibody
affinity, a process that involves follicular dendritic cells and T follicular helper (Tfh) cells. Many of
these B cells undergo apoptosis as the IgV gene mutations negatively impact antigen-binding or the
structure of the antibody. Positively selected B cells either recirculate back to the dark zone to undergo
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further rounds of proliferation and IgV hypermutation [4,20–22], or differentiate into PCs or memory
B cells [23–25]. A large fraction of GC B cells also undergo Ig class switch recombination. The initiation
and maintenance of the GC reaction and post-GC differentiation are the subject of transcriptional,
post-transcriptional and epigenetic control [21]. The transcriptional control of the GC reaction is
increasingly well understood. The transcriptional repressor B-cell lymphoma 6 (BCL6) is considered
the master regulator of the GC reaction, since it is essential for the establishment of the unique dark
zone program that allows for rapid proliferation and the introduction of somatic hypermutations
into the IgV genes without eliciting a DNA damage response [26]. B lymphocyte-induced maturation
protein 1 (BLIMP1; encoded by PRDM1) and interferon regulatory factor 4 (IRF4) are important
transcription factors at the GC exit; X box-binding protein 1 (XBP1) is downstream of IRF4 and BLIMP1
and sets up the secretory program of the PC [23]. c-MYC, which is expressed in a small fraction of light
zone B cells, is required for the recirculation of antigen-selected B cells back to the dark zone [27,28].
Abolishing the function of c-MYC in light zone B cells leads to the collapse of the GC structure, pointing
towards the essential role of this B-cell subset for the maintenance of the GC reaction. With regards to
NF-κB, studies in humans have provided insights into the expression pattern of NF-κB in the GC.
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Figure 1. Nuclear factor-κB (NF-κB) signaling pathway. The NF-κB signaling cascade comprises two 
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Figure 1. Nuclear factor-κB (NF-κB) si li athway. The NF-κB signaling cascade comprises two
separate pathways. The canonical pathway (left) is activated by signals through several cell surface
receptors, including the B-cell receptor (BCR), Toll-like receptor, and CD40. The activation results in the
nuclear translocation of the heterodimers constituted by the canonical NF-κB subunits RELA, c-REL and
p50 where they activate the transcription of target genes. The alternative pathway (right) is activated
by B cell-activating receptor (BAFFR), lymphotoxin-β receptor (LT-βR), and CD40. Proteasomal
degradation of p100 results in the generation of the major heterodimer of the alternative pathway
RELB/p52, which translocates to the nucleus and activates target-gene transcription. Only RELA,
RELB, and c-REL can transcribe target genes due to transactivation domains.
In humans, the vast majority of GC B cells are not subjected to NF-κB signaling; this includes
dark zone and most light zone B cells [29,30]. However, similar to c-MYC, NF-κB activation was
observed in a small subpopulation of light zone B cells, presumably via stimulation of the BCR
and the CD40 signal-transduction pathway, resulting in the nuclear translocation of canonical and
alternative NF-κB subunits [30,31]. This selective activation of NF-κB in a subset of light zone B cells
suggests roles for NF-κB transcription factor subunits in GC biology, and was experimentally addressed
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through the specific in vivo ablation of the individual NF-κB subunits using conditional alleles and
a Cre-recombinase that is expressed in GC B cells [31–33]. These studies, perhaps surprisingly,
have revealed that the separate NF-κB transcription factor subunits exert distinct biological functions
during GC and post-GC B cell development (Figure 2).
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Figure 2. Role of NF-κB subunits in the molecular control of germinal center (GC) initiation,
maintenance and differentiation. High-affinity PCs and memory B cells are generated in the GC
B-cell reaction (see text). At day 7 of the GC response, a mature, polarized GC microenvironment is
formed which comprises of a dark zon and a light zon . Dark zone GC B cells somatically hypermutate
their immunoglobulin variable (IgV) genes and move to the light zone where B cells are selected for
improved antibody affinity, a process that involves follicular dendritic cells and T follicular helper (Tfh)
cells. Positively selected B cells either recirculate back to the dark zone to undergo further rounds of
proliferation and IgV hypermutation, or differentiate into PCs and memory B cells. c-REL is required
for B-cell activation, wherea RELA is dispensable at thi stage. c-REL, and independently RELB/p52,
are required for the recirculation of an antigen-selected GC B cell from light to dark zone, and thus for
the maintenance of the GC reaction. Conversely, RELA is required for the differentiation of a GC B cell
into a PC precursor (plasmablast). The p52 subunit alone (i.e., it does not require RELB) is essential for
the physiology of PCs. Figure adapted from [21].
3.1. c-REL
Rel (c-REL) constitutional knockout mice generate a naïve B-cell repertoire comp rable to their
wild-type counterparts [34,35]. However, in vitro mitogen-stimulation experiments revealed the
requirement of c-REL during B-cell activation. Accordingly, Rel knockout mice showed impaired
formation of GCs following T-dependent immunization [36]. This is intrinsic to B cells, since GC
formation was strongly impaired in conditional Rel knockout mice with deletion of Rel in all B cells
using a CD19-Cre allele [37]. The role of c-REL during the GC reaction was investigated through the use
of conditional Rel knockout mice that expressed the Cre-recombinase in GC B cells (Cγ1-Cre mice) [32].
c-REL ablation in GC B cells led to the gradual collapse of the GC after day 7, which is the time-point at
which dark and light zones have formed and selection is thought to begin. Loss of dark zone and light
zone cells in c-REL-deficient GCs was concurrent and led to the almost complete disappearance of GCs
in the Rel conditional mice at day 14. These findings are reminiscent of those of the GC-specific ablation
of c-MYC [27,28] and suggest that also c-REL is required for cyclic re-entry of antigen-selected B cells
from the light zone to the dark zone. Gene expression profiling of c-REL-deficient GC B cells suggests
that c-REL is required in light zone B cells to establish a metabolic program that generates energy and
building blocks to facilitate cell growth [32]. In agreement with these observations, in vitro-stimulated
c-REL-deficient B cells were characterized by reduced metabolic activity compared to wild-type B cells.
While it is unclear to what extent c-MYC and c-REL crosstalk among each other, an NF-κB signature
is present in the c-Myc+ light zone subset [28], suggesting that c-REL and c-MYC are active in the
same subset of cells. A recent study that provides evidence that GC B cells rewire their BCR and CD40
signaling to enhance selection stringency in the GC suggests that the CD40-mediated activation of
NF-κB by Tfh cells is jointly required with BCR activation (which, unlike in naïve B cells, does not
Cells 2018, 7, 189 5 of 21
activate NF-κB in GC B cells) to induce c-MYC expression in GC B cells [38]. In summary, c-REL
shows a biphasic activation pattern at two stages of the GC reaction, as it is required during the T
cell-dependent antigen-activation phase preceding GC formation, and then several days later in the
fully established GC during the selection of light zone B cells for high-affinity antibodies.
3.2. NF-κB1
The inhibition of IKK complex-induced proteolysis of p105, which is the precursor of p50,
was found to impair the antigen-induced formation of GCs in murine B cells, similar to what has
been observed for Rel deletion in B cells [39]. Thus, the phenotype in the p105 mutant mice may
be due to their inability to process p105, which in turn prevents the formation and ultimately the
nuclear translocation of c-REL/p50 heterodimers. Conversely, the loss of p105 (which essentially is an
inhibitory κB protein for c-REL and RELA) in Nfkb1–/– mice (Nfkb1 is the gene encoding p105/p50)
may lead to enhanced c-REL activity in B cells, which might contribute to the increased formation of
spontaneous GCs that has been observed in aging NF-κB1-deficient mice [40].
3.3. RELA
Germline deletion of Rela (RELA) results in embryonic lethality at day 15 [41]. Experiments with
irradiated SCID mice reconstituted with Rela– fetal liver cells suggested that c-REL and RELA are
redundant during the generation of the naïve B-cell repertoire [42], a finding that was confirmed
in conditional Rel and Rela knockout mice crossed to CD19-Cre mice [37]. However, in contrast to
c-REL, RELA was dispensable for both the formation of GCs [37] and, as investigated by crossing
the conditional allele to Cγ1-Cre mice, for GC maintenance [32]. Intriguingly, the GC B cell-specific
deletion of Rela abolished the generation of GC-derived PCs [32]. This may at least in part be due
to a role of RELA in upregulating the expression of the PC master regulator BLIMP1 [32]. Of note,
mRNA and protein expression of RELA’s canonical counterpart c-REL is strongly downregulated in
normal human and murine PCs [31,43], indicating that RELA is the exclusive transcriptionally active
canonical NF-κB subunit in PCs.
3.4. RELB and NF-κB2
Combined GC-specific deletion of Relb (RELB) and Nfkb2 (p100/p52), but not that of the single
alternative NF-κB subunits, resulted in the collapse of established GCs [31], similar to what has been
observed for Rel deletion [32]. This suggests that the alternative NF-κB pathway is required for
GC maintenance in a non-redundant fashion with c-REL. RELB/p52 was found to be required for
cell-cycle progression. Moreover, evidence suggests that RELB/p52 is required in differentiating GC B
cells to set up a program that allows for the efficient production of proteins and facilitates antibody
secretion. Of note, p100/p52 was found to be strongly expressed in both PC precursors in the GC and
in subepithelial PCs in human tonsil compared to surrounding lymphocytes [31]. In agreement with
this finding, the deletion of Nfkb2, but interestingly not that of Relb, in GC B cells led to a dramatic
reduction in antigen-specific PCs [31], suggesting a critical role for p52 in the development and/or
physiology of PCs.
4. Aberrant Activation of NF-κB in Lymphoid Malignancies
The development of lymphoid malignancies is mechanistically tied to the deregulation of cellular
pathways, which govern the differentiation, proliferation, and survival of lymphocytes or PCs [6,44,45].
The NF-κB signaling pathway has functions in all of these cellular pathways. Perhaps not surprisingly,
constitutive NF-κB activity occurs in many lymphoid malignancies and can be activated by the tumor
microenvironment, tumor viruses or as the results of genetic alterations in NF-κB pathway components.
Especially the latter has become increasingly well understood over the last decade primarily, due to
next-generation sequencing efforts that could provide a clear pattern of the genetic aberrations leading
to aberrant NF-κB activity in the various lymphoid malignancies. From these studies, it has emerged
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that NF-κB’s role in lymphomagenesis varies depending on the tumor subtype; an overview of
subtypes, characteristics, genetic aberrations and NF-κB pathway involvement is presented in Table 1.
It has long been established that lymphomas and PC malignancies originate from the
malignant transformation of B cells and PCs at different stages of cellular differentiation (Figure 3).
The heterogeneity of lymphoma subtypes appears to be reflected by the marked heterogeneity of
GC B-cell subtypes. For example, whereas Burkitt lymphoma is consider to be a tumor of dark zone
B cells, follicular lymphoma and the GC-type of diffuse large B-cell lymphoma (GCB-DLBCL) are
thought to originate from the transformation of light zone B cells, and the normal counterpart of the
activated B cell-type DLBCL (ABC-DLBCL) may represent a differentiated late GC B cell destined
to become a PC [44]. Extrapolating the findings that canonical and alternative NF-κB subunits have
distinct functions in the various B-cell subsets which represent the normal counterparts of lymphoid
malignancies, identifying the roles of the individual oncogenic NF-κB transcription factors in these
tumor subtypes may be exploited for the development of more specific therapies that target aberrant
NF-κB activity. In the following, we will discuss the role of aberrant NF-κB activation in lymphomas
and PC malignancies with a particular emphasis on the potential involvement of the separate NF-κB
pathways and subunits in the disease process. Thereby, a special focus will be on MM and subtypes of
aggressive B-NHL, where oncogenic NF-κB signaling due to genetic mutations is particularly prevalent.
For a detailed discussion of the role of NF-κB in various lymphoma subtypes, we refer to excellent
reviews [46–49].
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Figure 3. GC B-cell development and cellular derivation of B-lineage malignancies. Whereas Burkitt
lymphoma seems to originate from the transformation of dark zone cells, recent evidence suggests that
follicular lymphoma and germinal center B-cell type (GCB)-DLBCL may derive from the transformation
of light zone cells (see text). Activated B-cell type (ABC)-DLBCL is thought to originate from light
zone cells poised to undergo PC differentiation. Conventional mantle cell lymphoma (MCL) may
derive from the oncogenic transformation of an antigen-activated pre-GC B cells. Multiple myeloma
is a tumor of bona fide PCs. Hodgkin lymph ma is thought to originate from light zone B c lls with
“crippled” antigen receptors, ediastinal large B-cell lymphoma from a differen iation light zone B cell,
and MZL from a post-GC marginal zone/memory B cell. Chronic lymphocytic leukemia (CLL) can
have unmutated and mutated IgV genes. Several mature B-lineage malignancies show constitutive
NF-κB activity, as indicated.
Cells 2018, 7, 189 7 of 21
4.1. Diffuse Large B-Cell Lymphoma
DLBCL constitutes ~35% of B-NHLs and is a morphologically, genetically and clinically
heterogenous disease. DLBCL subtypes are commonly classified according to their cell of origin
(COO), delineating GCB-DLBCL, ABC-DLBCL and an unclassified subtype [50,51]. The ABC-DLBCL
subtype is associated with an unfavorable prognosis and shows a more aggressive disease course
compared to its GCB-DLBCL and unclassified DLBCL counterparts. Recent genomic studies that
molecularly profiled (mRNA, DNA alterations) large numbers of DLBCL cases have provided a more
refined subdivision of DLBCL cases into genetically defined subgroups [52–54], ranging from 4 [53]
and 5 [54] to 39 [52] subtypes. Whilst the ultimate goal should be to classify all DLBCLs according to
their molecular lesions in order to personalize DLBCL treatment, currently the COO classification is still
useful; for example, only 50% of cases fall into the classification scheme by Schmitz and colleagues [53],
with the remaining cases being attributed to ABC-, GCB- or unclassified DLBCL subtypes.
More than 80% of ABC-DLBCL cases show genetic aberrations leading to aberrant NF-κB
activation, which is considered a hallmark of this DLBCL subtype [6]. Initially, genetic mutations have
been identified in regulators of the BCR (CARD11, CD79A, CD79B) and Toll-like receptor (MYD88)
signaling pathways, leading to dysregulated NF-κB activation downstream of these pathways, as well
as in a negative regulator of the NF-κB pathway (TNFAIP3, encoding A20) [55–61]. Mutations have
subsequently been identified in several other NF-κB pathway components that lead to constitutive
NF-κB activity in ABC-DLBCL [57,62,63]. Recently, an oncogenic BCR signaling supercomplex
(MyD88-TLR9-BCR) has been identified in ABC-DLBCL which has been shown to activate NF-κB [64].
This complex facilitates synergistic signaling and crosstalk by clustering the BCR, CD79a, CD79b,
MyD88 and associated proteins, including the IKKs, on the endolysosome membrane to allow
for efficient downstream signaling largely through NF-κB. Tumors with the MyD88-TLR9-BCR
supercomplex were generally associated with sensitivity to inhibition of the BCR signaling pathway
by ibrutinib (see below) [64].
Only a small fraction of GCB-DLBCLs show NF-κB activation [6,57]. Amplification of
the REL locus (encoding c-REL) can be detected in a subset of GCB-DLBCL cases; however,
REL amplification is not associated with nuclear c-REL translocation [65]. It has therefore been
proposed that enhanced c-REL activity provided by the amplification may have been required early in
GCB-DLBCL pathogenesis, before becoming dispensable for tumor growth at later stages of tumor
development [66].
Among the recently identified molecular DLBCL subtypes, genetic aberrations in NF-κB pathway
components occurred predominantly in an ABC-DLBCL-related subset with MYD88L625P and CD79B
aberrations (MCD [53]; cluster 5 [54]) and in a subset with BCL6 fusions, NOTCH2 mutations and
TNFAIP3 lesions (BN2 [53]; cluster 1 [54]) that includes cases of ABC-, GCB- and unclassified DLBCL.
Regardless of the DLBCL classification method, the pattern indicates that genetic aberrations in NF-κB
pathway components in DLBCL predominantly correlate with a more aggressive clinical course.
This notion is supported by the finding of Reddy and colleagues that genetic mutations in NFKBIA
(encoding IκBα) occur in the GCB-DLBCL subtype, which is usually considered to show favorable
prognosis, and are associated with a poor prognosis [52].
In DLBCL, the vast majority of alterations in NF-κB pathway components activate the canonical
pathway. Mutations leading to aberrant activity of the alternative pathway were observed in ~10% of
DLBCL cases and can occur in both ABC-DLBCL and GCB-DLBCL subtypes [67]. Of note, altogether
~25% of cases show nuclear p52 translocation [57], suggesting a broader role for this pathway in DLBCL
pathogenesis. Mutations frequently target TRAF2 and TRAF3 that normally control the degradation
of the central upstream regulator NF-κB-induced kinase (NIK) [67], thus constraining the alternative
pathway from being activated. The role of aberrant NIK activity in driving DLBCL lymphomagenesis
has been verified in a mouse model with constitutive transgenic NIK and BCL6 expression in GC and
post-GC B cells [67].
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The observation that the canonical or alternative NF-κB pathways can be found activated by
genetic mutations in DLBCL may reflect the heterogeneity with regards to the cellular counterparts
of the lymphomas. In normal GC B cells, both the canonical subunit c-REL, and in a mutually
exclusive fashion, the alternative NF-κB subunits were found to be required for the maintenance
of the GC reaction (see above). Aberrant activity of the subunits may promote tumorigenesis in
the DLBCL-precursor cell, which could be an antigen-selected light zone B cell that is instructed
to recirculate to the dark zone, by disturbing the normal dynamics of this developmental step [68].
ABC-DLBCL is thought to originate from a later developmental stage in the GC, i.e. from a selected GC
centrocyte that is destined to differentiate into a PC. It will be interesting to determine whether RELA is
the major canonical NF-κB subunit involved in the pathogenesis of ABC-DLBCL with aberrant NF-κB
acticity, as this subunit was found to be required for PC development in vivo (Figure 2). Dysregulated
RELA activity may promote lymphomagenesis by forcing a biological program onto the cell that is
related to aspects of PC physiology.
4.2. Mantle Cell Lymphoma
MCL is a rare B-NHL subtype that is characterized by an aggressive clinical course [69].
The normal cellular counterpart of conventional MCL, the most common form of MCL, is thought to
be an activated mature B cell with no or few of IgV hypermutations, indicating a pre-GC origin [70]
(Figure 3). Although the fraction of MCL cases showing aberrant NF-κB activation and/or genetic
mutations in NF-κB pathway components is presently unknown, it seems that similar to DLBCL, MCL
cases can have either the canonical or alternative NF-κB pathway activated [69]. MCL cell lines that
are sensitive to inhibitors of BCR signaling showed activation of the canonical NF-κB pathway [71].
Of note, cell lines insensitive to BCR inhibition displayed activation of the alternative pathway [71].
In accordance, recurrent genetic aberrations in the upstream regulators TRAF2 and BIRC3 were
identified in ~15% of patients [71]. Interestingly, MCL lines with alternative NF-κB-pathway activity
were sensitive to the pharmalogical inhibition of IKKβ, a central activator of the canonical pathway [71].
This finding suggests crosstalk between the two NF-κB pathways in MCL, at least in these cell lines.
If the MCL precursor cell indeed represented an activated pre-GC B cell, one may speculate that, based
on the in vivo observation that c-REL is required for B-cell activation prior to the GC reaction, whereas
RELA is dispensable at this step [32] (Figure 2), c-REL may represent the critical NF-κB subunit in
MCL pathogenesis (Figure 3).
4.3. Multiple Myeloma
MM is an aggressive cancer of PCs. Molecularly heterogeneous genetic aberrations cause
dysregulated expression of various proto-oncogenes or inactivation of tumor suppressor genes,
thus promoting MM pathogenesis [45,72]. Both the canonical and alternative NF-κB pathways can be
activated in MM by signals from the bone marrow microenvironment. Nuclear translocations of RELA
and RELB were observed in around 80% and 40% of primary MM cases, respectively [73,74]. Several
groups have identified genetic mutations in NF-κB pathway components causing constitutive NF-κB
activity in ~20% of primary MM and ~40% of MM cell lines [73,75–80]. The fraction of NF-κB-mutated
cases may be higher, as an NCRI Myeloma-XI trial-based copy-number alteration study revealed that
half of cases carried at least one deletion of NF-κB-pathway genes [81].
The genetic aberrations in MM are thought to allow for stromal-independent tumor-cell growth.
~70% of the mutations target components of the alternative NF-κB pathway, including amplifications
and translocations of MAP3K14 (encoding NIK), CD40 and LTBR (encoding lymphotoxin-β receptor),
and deletions or inactivating mutations of TRAF3/TRAF2, and cIAP1/2 (BIRC2/3). All of these
alterations lead to aberrant expression of NIK, the major usptream regulator of the alternative pathway.
~30% of the mutations are associated with activation of the canonical NF-κB pathway. Besides CD40,
which activates both canonical and alternative NF-κB signaling, these include CYLD, TACI, and NFKB1
(encoding p105/p50). Somewhat surprisingly, MM cell lines with aberrant NIK expression also
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showed activation of the canonical pathway [73,75,76,82]; shRNA-mediated knockdown of NIK and
the pharmacological inhibition on IKKβ, the central regulator of the canonical pathway, was toxic
to these cell lines. This indicates that NIK-mediated activation of the canonical NF-κB pathway was
required for MM cell line growth [73,83,84]. Since shRNA-mediated knockdown of the alternative
NF-κB subunits RELB or p52 in MM lines, as expected, was reported to cause cell death [74,85],
the findings by Annunziata et al. suggest that both NF-κB pathways are active and promote cell
growth/survival in MM in cases with genetic mutations, leading to constitutive NIK expression (which
comprise a major fraction of NF-κB-mutated MM cases). Future work will determine to what extent the
inhibition of either NF-κB pathway (or their downstream subunits) is sufficient to interfere with MM
tumor cell growth, or whether both pathways need to be functionally ablated, as proposed by others.
Of note, since the canonical subunit c-REL does not appear to be expressed in PCs and MM [31,43],
the development of therapeutic strategies to inhibit the canonical pathway may focus on RELA/p50.
4.4. Other B-Cell Malignancies
Aberrant activation of NF-κB signaling occurs in several indolent lymphomas (Table 1). CLL is a
non-Hodgkin lymphoma of the elderly where activation of the NF-κB pathway is long known to be
involved in the pathogenesis [86]. Importantly, NF-κB is activated by the tumor microenvironment [87],
upon which signals are propagated intracellularly, following signaling through NF-κB-activating cell
surface receptors, including BCR, TLR, CD40 and BAFFR. Furthermore, epigenetic modifications and
aberrant methylation of the genes-encoding tumor-suppressing miRNAs have been shown to activate
NF-κB in CLL [88]. Although a wide range of genetic mutations in both canonical and alternative
pathway components have been identified in CLL (including MYD88, NFKBIE and BIRC3) [89–95],
these mutations occur at a low frequency [95]. Proceeding on the finding that the canonical subunit
RELA was implicated in fludarabin resistance [96], it will be interesting to dissect the functions of the
individual NF-κB pathways and subunits in CLL pathogenesis.
The finding that more than 90% of cases of Waldenström Macroglobulinemia (WM), a non-Hodgkin
lymphoma with plasmacytic features, have MYD88L265P mutations [97,98] implicates a crucial role of
the aberrant activity of the canonical NF-κB pathway in this disease.
Constitutive NF-κB-pathway activation is a hallmark of Hodgkin lymphoma (HL) [99,100]. A large
fraction of HL cases are associated with Epstein-Barr virus (EBV), the genome of which encodes
LMP1, a potent NF-κB activator. Genetic mutations in HL predominantly affect canonical NF-κB
pathway components [101,102], with a subset of cases harboring aberrations in components of the
alternative pathway [103,104]. Similar to GCB-DLBCL [51], HL and mediastinal large B-cell lymphoma
(MLBCL; a DLBCL subtype that is phenotypically related to HL) show amplifications of the REL
locus [105–107]. Unlike GCB-DLBCL [65], however, both HL and MLBCL cases display nuclear
translocation of c-REL [105,108,109], implicating a role for c-REL in the maintenance of HL and MLBCL
tumor cells. Also the alternative pathway is activated in HL cells, as signaling through CD30, CD40
and LMP1 activates both the canonical and alternative NF-κB pathways [99]. This is reflected by
siRNA knockdown experiments of RELA-p50 and RELB-p52 in an HL cell line that showed a greater
decrease in cell viability in the latter knockdown (95% vs. 40%) [110]. Of note, the effect of c-REL
knockdown has not been tested in this study. It appears that in HL, the aberrant activity of both NF-κB
pathways is involved in the disease mechanism. The same appears to be the case for splenic marginal
zone lymphomas and mucosal-associated lymphoid tissue (MALT) lymphomas [47,48] (Table 1).
Finally, although in the human, Burkitt lymphoma is not normally associated with aberrant NF-κB
activation, a mouse model that develops a MYC-driven, Burkitt-like disease represents a useful tool
to study the mechanism of NF-κB-pathway components in tumorigenesis. Using the Eµ-Myc mouse
model, Hunter and colleagues could attribute a pathogenic role to a single NF-κB subunit, namely
c-REL [111], providing further rationale for the need to dissect the functions of the individual NF-κB
transcription factor subunits in lymphoid malignancy.
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5. NF-κB as a Therapeutic Target in Lymphoid Malignancies
The crucial role of aberrant activation of the NF-κB pathway in the pathogenesis of lymphoid
malignancies have identified targeting of aberrant NF-κB signaling as a logical treatment strategy for
these diseases [71,99,112]. Genetic aberrations upstream of Bruton tyrosine kinase (BTK) in the BCR
signaling pathway can be successfully treated by a small molecule inhibitor of BTK, ibrutinib [113].
Besides the phosphoinositide 3-kinase (PI3K) pathway, BTK inhibition blocks the activation of the
canonical NF-κB pathway. However, mutations in the BTK protein have been found in CLL and MCL,
which confer resistance and limit the efficacy of the drug [114], indicating the need for alternative
treatment strategies. Proteasome inhibitors prevent degradation of the canonical NF-κB inhibitor
IκBα among many other proteins, in addition to the initiation of the unfolded protein response
(UPR) by the build-up of protein, which is thought to contribute to their toxicity [115]. The first
generation proteasome-inhibitor bortezomib was found to be highly effective in the treatment of
refractory MM [116]. However, in MM cells, bortezomib was observed to induce canonical NF-κB
activation [117,118], suggesting that bortezomib-induced toxicity in MM cells cannot be fully attributed
to inhibition of canonical NF-κB activity. Similarly, it is not clear to what extent NF-κB inhibition
contributes to bortezomib-mediated cell toxicity in MCL [119–121]. Nevertheless, bortezomib is
currently used in combinatorial frontline therapies for MM and MCL [122]. In DLBCL, bortezomib
showed initial success in the treatment of ABC-DLBCL, but not GCB-DLBCL, when combined with
chemotherapy [123,124]. This may be explained by the activation of NF-κB through chemotherapeutic
agents, although it was unclear whether the improved response in the combination treatment was
due to bortezomib-induced NF-κB inhibition [123]. Small-molecule inhibitors of IKKβ activity
are potent inhibitors of canonical NF-κB signaling in many in vitro settings [125,126]. However,
although IKKβ inhibitors have been available since long and were tested in clinical trials, it appears
their toxicity renders them unsuitable for therapeutic use [127–130]. Moreover, strategies to inhibit
upstream NF-κB-pathway components need to take into consideration possible NF-κB-independent
functions [131], as shown for IKKβ [128,132].
Overall, it emerges that current therapeutic approaches aimed at inhibiting aberrant NF-κB
signaling lack specificity. More generally, a serious problem associated with the use of global NF-κB
inhibitors in cancer therapy is that NF-κB activation virtually plays a role in every cell type. Therefore,
treatment with NF-κB inhibitors could lead to systemic toxicity [133], thereby limiting their usability
and efficacy.
In order to develop more effective therapies aimed at aberrant NF-κB activity while avoiding
systemic toxicity, strategies are required to selectively target the specific NF-κB signaling components
that are oncogenic within the malignancies. It is becoming clear that understanding the mechanism
of pathogenic NF-κB activity in malignancy must focus on identifying the oncogenic functions of the
separate NF-κB transcription factor subunits—the downstream mediators of NF-κB activation [134],
and of the specific target genes of these subunits [122]. Initial efforts in this direction have been made.
A promising approach is to target the survival-mediating, downstream effectors of NF-κB, as recently
described for the GADD45β/MKK7-complex in an MM xenograft model [135]. Additionally, a newly
developed small molecule c-REL inhibitor showed anti-cancer cell properties in a xenograft model [136],
although this inhibitor may not be c-REL-specific as it inhibited RELA function in another study [137].
Proteolysis-targeting chimeras (PROTACs) are a novel class of compounds that harness the
power of the ubiquitin–proteasome pathway to selectively degrade cellular proteins of interest,
thus comprising a specific targeting strategy. The term was coined in 2001 following the generation of
a compound which recruited a protein of interest to an E3-ligase via two binding moieties attached by
a linker [138]. Proof of principle work using a PROTAC to degrade BRD4 in lymphoid malignancies
was independently shown in Burkitt lymphoma [139], acute myeloid leukemia [140], and MCL [141].
More recently, BTK was successfully targeted by PROTAC-mediated degradation in ibrutinib-sensitive
and resistant lymphoma cell lines, which may comprise a promising strategy for the treatment of
BTK-resistant tumor cases [142]. In this study, the corresponding PROTAC demonstrated a reduction
Cells 2018, 7, 189 11 of 21
in off-target effects on other kinases normally implicated by the use of ibrutinib [142]. Overall, the work
on PROTAC strategies thus far demonstrates the scope of this approach for the specific targeting of
intracellular proteins and could hence be harnessed to specifically target downstream NF-κB subunits
or their effectors.
6. Conclusions and Outlook
There is increasing evidence that in certain lymphoid malignancies, the oncogenic effects of
aberrant activation of the NF-κB signaling pathway, either via the tumor microenvironment or through
cell-intrinsic genetic mutations, can be mediated by distinct downstream effectors. These effectors
include the canonical and alternative NF-κB pathways, and the separate NF-κB transcription factors
as well as their target genes. This selectivity may be exploited for the development of more specific
NF-κB-inhibitory therapies. In tumor entities where the activity of both the canonical and alternative
NF-κB pathways has been implicated in the pathogenesis (e.g., HL, MM) (Table 1), it will be important
to identify the individual contributions of either pathway, and to determine the extent to which the
functional ablation of the separate pathways affects tumor cell growth or survival. These efforts are
expected to provide the rationale and mechanistic basis for the development of more specific, less toxic
NF-κB inhibitors against these malignancies.
It is becoming increasingly clear that the separate NF-κB subunits have known pathogenic roles in
many cancers, either within the cancer cell or in cells of the tumor microenvironment [143–145].
This includes inflammation-associated cancers, which has implications for immunotherapy.
As a recent example, specifically ablating c-REL function in murine Treg cells delayed melanoma
growth by impairing Treg-mediated immunosuppression, and potentiated the effects of anti-PD-1
immunotherapy [146]. Therefore, understanding the roles of individual NF-κB subunits in both tumor
cells and cells of the tumor microenvironment has the potential to inform the development of new
treatment strategies.
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Table 1. Characteristics of lymphoma subtypes and NF-κB involvement.
Subtype Characteristics & Main Genetic Aberrations NF-κB Involvement
N
on
-H
od
gk
in
’s
Ly
m
ph
om
a
BL Aggressivet(8;14) MYC Rare or no involvement of NF-κB [147].
CLL
Indolent
Highly heterogeneous disease, comprising two main subtypes 60% are IGHV-mutated (good
prognosis) and 40% are IGHV-unmutated (poor prognosis) [86,148]. Large range of genetic
aberrations [95].
NF-κB pathway constitutively active by stimulation of cell surface receptors and tumor–microenvironment
interactions. Genetic mutations in NF-κB pathway components affect both the canonical and alternative
pathway, but occur at low frequency (See text).
D
LB
C
L
ABC-DLBCL Genetic mutations in genes encoding
histone/chromatin modifiers; genetic abnormalities
targeting BCL6; evasion of immune surveillance by
lack of MHC class I expression [6,149].
Aggressive
MYD88; CD79A/B; TNFAIP3;
PRDM1; CDKN2A/B; CARD11
Constitutive NF-κB pathway activation in >80% of cases. Genetic mutations in various NF-κB pathway
components, including CARD11, CD79A/B, MYD88, TNFAIP3, TRAF3. Only 10% of mutations affect the
alternative pathway, although 25% of cases show nuclear p52, includes MCD [53] and cluster 5 [54] subtypes, as
well as a fraction of BN2 [53] and cluster 1 [54] subtypes (See text).
GC-DLBCL
Indolent *
BCL2; MYC translocations; EZH2;
GNA13; PTEN
Constitutive NF-κB activation is rare. REL amplification, although lack of correlation with nuclear c-REL
translocation. Includes fraction of BN2 [53] and cluster 1 [54] subtypes and the aggressive subtype with genetic
mutations in NFKBIA [52] (See text).
Unclassified IndolentLymph-node signature [51]. Includes fraction of BN2 [53] and cluster 1 [54] subtypes (See text).
PMBCL AggressiveAffects young adults (predominantly females).
Constitutive NF-κB signaling. TNFAIP3 is mutated in ~35% of cases [101]. REL amplification in 20–50% of cases
(See text.)
FL Indolent (aggressive following histological transformation to DLBCL) [150,151]t(14;18) BCL2 NF-κB involvement in transformed FL [152,153].
MCL
Aggressive
t(11;14) CCND1
Additional diverse molecular events: deregulation of cell cycle, DNA damage repair,
apoptosis and chromatin modifiers [69].
Canonical NF-κB pathway activation (in cell lines sensitive to BCR inhibitors) and alternative pathway
activation (in cell lines insensitive to BCR inhibitors). Recurrent mutations in TRAF2 or BIRC3 in 15% of
patients (See text).
M
Z
L MALT
Indolent
t(11;18) c-IAP2 and MALT1 fusion [47,48]
Helicobacter Pylori infection associated [154]
c-IAP2 and MALT1 fusion protein induces robust activation of canonical and alternative NF-κB pathways.
TNFAIP3 deletions [47,48].
Other Indolent TNFAIP3. [155] Activate canonical and alternative pathway activation at almost equal fractions [156].
WM
Indolent
IgM-secreting lymphoplasmacytic lymphoma
MYD88 [97,98]
Gain of function MYD88 mutation in 90% of cases, which activates the canonical pathway via TLR signaling
(See text).
Hodgkin’s Lymphoma Indolent~50% EBV-associated [157]
EBV-associated LMP1 is a potent NF-κB activator. 20% and 40% inactivation/deletion of NFKBIA and TNFAIP3
(preferentially in EBV-negative cases) REL amplification in ~40% of cases (See text.)
MM
Aggressive
Molecularly heterogeneous genetic aberrations, including cyclin D/retinoblastoma
pathway [45,72]
Constitutive canonical and alternative NF-κB pathway activation. NF-κB activating signals from tumor
microenvironment. Majority of genetic alterations in NF-κB affect alternative pathway (>70%), including
MAP3K14 (NIK), CD40, LTBR, TRAF2/TRAF3, cIAP1/2, leading to aberrant NIK activity. Genetic mutations in
canonical pathway include CYLD, TACI, and NFKB1. Aberrant NIK activation also activated canonical pathway
(See text).
* aggressive GC-DLBCL has also been described: The ‘double-hit lymphomas’ (DHL) are characterized by translocation of MYC and BCL2 (or less commonly BCL6) [149]. ABC, activated B
cell; BL, Burkitt lymphoma; CLL, chronic lymphocytic leukaemia; DLBCL, diffuse large B-cell lymphoma; EBV, Epstein-Barr virus; FL, follicular lymphoma; GC, germinal center; HL,
Hodgkin’s lymphoma; MCL, mantle cell lymphoma; MALT, mucosa-associated lymphoid tissue; MM, multiple myeloma; MZL, marginal zone lymphoma; PMBCL, primary mediastinal
B-cell lymphoma; WM, Waldenström’s macroglobulinemia.
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